Arrow image

10 Sep 2024

FDA Rule on Lab Developed Tests (LDTs)

2 | Understanding Compliance Tiers for Laboratory Developed Tests (LDTs)

WRITTEN BY

Divya Anantsri

SHARE THIS

Blog

In our previous blog in this series, we summarized the FDA’s plan to phase out the enforcement discretion policy for LDTs. To recap, the phase-out policy involves five stages spread across five years.

 

In this blog, we will elaborate on which rules apply to the various types of LDTs.

The types of compliance required are divided into Tiers 0-IV, as shown in the table below.

Tier 0 lists tests for which the compliance required by the final rule is already expected and enforced.

 

Thus, the stringency of compliance depends on the type of LDTs being manufactured.

If you are a new molecular LDT manufacturer, watch out for our next blog, which will elaborate on the specific processes that need to be set up and, importantly, how Strand can help.

 

Explore the rest of the blog series below:

Today’s Pick
from Blogs

26 Jun 2025

Strand’s qPCR Reporting Platform Accelerates Infectious Disease Diagnosis With ~2 min Turnaround Times

Sharon Christella

Know More

23 Jun 2025

From Raw Data to Real-World Insights Through Strand’s Data Harmonization and Curation Capabilities

Chinta Sidharthan

Know More

Your Next
Blog Recommendations

27 Mar 2023

Chris Hemsworth and the risk of Alzheimer’s Disease

Dr. Ramesh Hariharan

Know More

24 Nov 2023

Navigating the Cell-Free DNA landscape: Recommendations from AMP

Divya Anantsri

Know More

13 Dec 2024

Strand’s Methylation Pipeline Series

1 | Strand’s Methylation Pipeline - An Overview - Part 1

Divya Anantsri

Know More

Let's
Talk

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Form
About image
Please fill out this form to
download the case study.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.